German lawmakers are advancing proposals aimed at eliminating discrimination against cancer survivors who have been in remission for several years. The initiative, known as the “right to be forgotten” (RTBF), seeks to protect those who have been medically cleared of cancer from enduring disadvantages in areas such as insurance, bank loans, adoption, and employment.

The Social Democrats (SPD), a junior partner in Germany’s coalition government, have spearheaded the policy push in response to concerns from an estimated 5.5 million former cancer patients. The proposal argues that once a medically justified period—typically five years—has elapsed without recurrence, individuals should no longer be required to disclose their past cancer diagnosis.

Prominent advocates for the legislation include SPD parliamentarian Adis Ahmetovic, who publicly shared his lymphoma diagnosis at age 30 and has been tumor-free since October 2024. Ahmetovic emphasizes the ethical importance of the change and notes that it would not impose additional costs on the state. Support has also come from Manuela Schwesig, the SPD-led premier of Mecklenburg-Western Pomerania. Schwesig criticized Germany’s current stance as out of step with other European countries, stating that “other European countries have long since sorted this out” and calling for legislation to provide former cancer patients with a fresh start.

Lars Klingbeil, co-leader of the SPD and Germany’s finance minister, who survived tongue cancer after being diagnosed in 2014, has also voiced support for the RTBF initiative.

The campaign has gained momentum in the public sphere, with a petition backing RTBF reforms gathering more than 55,000 signatures. The petition was launched by Tobias Burggraf, whose daughter was diagnosed with cancer at two and a half years old. Burggraf highlighted the need to focus on life after recovery, describing the proposal as addressing “the thrust of our petition” and calling it “long overdue.”

However, the German Insurance Association has expressed opposition to the introduction of fixed time limits in assessing cancer survivors’ health status for insurance purposes. The group argues that private insurers must retain the ability to evaluate future risks based on scientific data and medical assessments to maintain affordable policies for all clients.

As the debate continues, proponents of the RTBF underscore the balance between protecting cancer survivors from undue discrimination and ensuring the sustainability of insurance systems, with the ongoing discussion expected to shape future legislation.